You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 7571 results
  1. Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARYThe goal of this proposal is to optimize and clinically validate a new diagnostic test for eosinophilic chronic rhinosinusitis (eCRS) at the point-of-care, improving the efficiency, value, and accessibility of personalized medicine. eCRS affects up to 5 million Americans and is characterized by varying degrees of sinonasal and peripheral eosinophilia, linked to treatment responsiven ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting TLR4-lipid rafts to prevent postoperative pain

    SBC: RAFT PHARMACEUTICALS LLC            Topic: 108

    PROJECT SUMMARY Postoperative pain is a prevalent source of pain requiring appropriate management to reduce its impact upon quality of life. Even with the availability of several analgesics, postoperative pain is often undermedicated because of concern related to the adverse consequence of the available therapeutics (e.g., NSAIDs and opiates), including addiction and decreased survival of cancer p ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. A Precision Medicine for Alcohol-Associated Liver Disease

    SBC: GENETOBE INC            Topic: 150

    ABSTRACT The goal of this study is to develop an RNAi-based genetic precision medicine to treat alcohol associated liver disease (AALD). AALD is a devastating health problem worldwide, accounts for the majority of alcohol-related mortality globally and is the second most indication for liver transplantation in the US. The current medical management for AALD remains limited, and no proven pathobiol ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. PANK Activators for the treatment of pantothenate kinase-associated neurodegeneration

    SBC: Virtus Therapeutics Corporation            Topic: NINDS

    SUMMARY Pantothenate kinase-associated neurodegeneration, PKAN, is a rare progressive neurodegenerative disorder associated with iron accumulation in the brain. The disease causes early immobility and often death by early adulthood. PKAN is caused by mutations in one of four human pantothenate kinase genes, PANK2 gene, which encodes a mitochondrial pantothenate kinase. Consistent with the clinical ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Treatment of status epilepticus and refractory status epilepticus with intravenous topiramate.

    SBC: PREVEP, LLC            Topic: NINDS

    Abstract Status epilepticus (SE) is a common neurologic emergency that fails to respond to first- and second-line anti-seizure medications (ASMs) in about one third of instances, thus progressing to refractory SE (RSE). Patients with RSE are at grave risk for neurological morbidity and mortality. The recently completed NIH-funded Established SE Treatment Trial (ESETT) highlights the need for impro ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Addressing the wireless power problem: A low-power hybrid radio for neuroscience experiments

    SBC: SPIKE NEURO LLC            Topic: 101

    Project Summary Closed-loop stimulation is key to the study and treatment of neurological disorders. However, largely due to current wireless power demands, stimulation systems are restricted to wired connections, which impact natural behavior, induce motion artifacts, and limit complexity of study design. While a few wireless recording- only systems have been developed, the power demands of these ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Staph Aureus Vaccine

    SBC: BIOLOGICAL MIMETICS, INC.            Topic: NIAID

    Abstract Methicillin-resistant Staphylococcus aureus is often considered the prototype hospital-acquired infection. In spite of the billions of dollars spent on preventive measures, estimates of the incidence are in the hundreds of thousands, with tens of thousands of people per year succumbing to disease in the USA alone. Prophylactic vaccines against S. aureus would have an enormous impact in th ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro

    SBC: SANARIA INC.            Topic: NIAID

    In 2022 WHO called for highly efficacious vaccines against malaria that prevent Plasmodium falciparum (Pf) infection in rt 90% of recipients. Alone among malaria vaccines, Sanaria® PfSPZ (Pf sporozoite (SPZ)) vaccines have shown rt 90% vaccine efficacy (VE) against controlled human malaria infection and VE against intense field transmission of malaria to pregnant women for two transmission years ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase

    SBC: AFASCI, INC.            Topic: 150

    7. SUMMARY Alcohol use disorder (AUD) is the most prevalent substance use disorder worldwide and often co-occurs with chronic pain, anxiety, depression, and opioid dependence. Unfortunately, currently available medications for AUD have limited efficacy with unwanted side effects. To address this unmet medical need, we propose an SBIR Phase I U43 project in response to PAR-22-102 "Investigational N ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical validation of mGlu2 PAMs in alcohol use disorder

    SBC: Camino Pharma, LLC            Topic: 150

    PROJECT SUMMARY Alcohol Use Disorder (AUD) continues to be a significant problem, affecting 28.3 million adults in the United States, and is the third leading preventable cause of death. Disulfiram, naltrexone, and acamprosate are the only drugs approved by the Food and Drug Administration, but all three have limited efficacy and several contraindications. Given the substantial burden on society a ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government